How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/genitourinary-tract-infection-due-to-proteus.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Genitourinary Tract Infection due to Proteus — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Genitourinary Tract Infection due to Proteus (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Genitourinary Tract Infection due to Proteus, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Amoxil	amoxicillin	Generic (originally Beecham/GSK)	Aminopenicillin (Beta-lactam antibiotic)	5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C	1972-01-01
Amoxycillin	Amoxycillin	King George's Medical University		5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C
Amoxicilli	Amoxicilli	Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.		5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Generic (originally Beecham/GSK) · 1 drug in Genitourinary Tract Infection due to Proteus
King George's Medical University · 1 drug in Genitourinary Tract Infection due to Proteus
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. · 1 drug in Genitourinary Tract Infection due to Proteus

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Genitourinary Tract Infection due to Proteus:

Cite this brief

Drug Landscape (2026). Genitourinary Tract Infection due to Proteus — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/genitourinary-tract-infection-due-to-proteus. Accessed 2026-06-10.

Genitourinary Tract Infection due to Proteus full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing